Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
NLS Pharmaceutics AG (NASDAQ: NLSP) stock has more than doubled in reaction to a License Agreement with Novartis Pharma AG, a unit of Novartis AG (NYSE: NVS), wherein NLS secured an exclusive license to Sanorex (mazindol) in the U.S.
- Sandoz developed Sanorex as an immediate-release obesity drug designed to shed pounds fast.
- The agreement encompasses all preclinical and clinical studies, data used for manufacturing, formulation data, and know-how for all products containing mazindol as an active substance, post-marketing clinical studies, and periodic safety reports.
- Under the agreement, NLS has obtained the same rights on a non-exclusive basis outside the U.S., except for Japan.
- The agreement includes the right to sublicense or assign the license to third parties.
- NLS went public in January this year and priced its IPO at $4.15 per unit.
- Price Action: NLSP shares have surged 123.4% at $6.29 in market trading hours on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!